|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC6A11 |
Gene summary for SLC6A11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC6A11 | Gene ID | 6538 |
| Gene name | solute carrier family 6 member 11 | |
| Gene Alias | GAT-3 | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001504 | UniProtAcc | P48066 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6538 | SLC6A11 | P5T-E | Human | Esophagus | ESCC | 9.56e-08 | 1.77e-01 | 0.1327 |
| 6538 | SLC6A11 | P10T-E | Human | Esophagus | ESCC | 3.50e-02 | 9.83e-02 | 0.116 |
| 6538 | SLC6A11 | P21T-E | Human | Esophagus | ESCC | 5.00e-17 | 3.08e-01 | 0.1617 |
| 6538 | SLC6A11 | P22T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.15e-01 | 0.1236 |
| 6538 | SLC6A11 | P36T-E | Human | Esophagus | ESCC | 1.12e-06 | 2.51e-01 | 0.1187 |
| 6538 | SLC6A11 | P49T-E | Human | Esophagus | ESCC | 1.19e-10 | 9.76e-01 | 0.1768 |
| 6538 | SLC6A11 | P52T-E | Human | Esophagus | ESCC | 7.55e-03 | 6.07e-02 | 0.1555 |
| 6538 | SLC6A11 | P80T-E | Human | Esophagus | ESCC | 4.12e-02 | 1.26e-01 | 0.155 |
| 6538 | SLC6A11 | P91T-E | Human | Esophagus | ESCC | 3.82e-08 | 7.73e-01 | 0.1828 |
| 6538 | SLC6A11 | P128T-E | Human | Esophagus | ESCC | 3.21e-06 | 2.54e-01 | 0.1241 |
| 6538 | SLC6A11 | P130T-E | Human | Esophagus | ESCC | 1.53e-19 | 3.91e-01 | 0.1676 |
| 6538 | SLC6A11 | NAFLD1 | Human | Liver | NAFLD | 9.16e-04 | 3.81e-01 | -0.04 |
| 6538 | SLC6A11 | HCC1_Meng | Human | Liver | HCC | 1.42e-23 | 7.01e-02 | 0.0246 |
| 6538 | SLC6A11 | HCC1 | Human | Liver | HCC | 8.12e-15 | 1.32e+00 | 0.5336 |
| 6538 | SLC6A11 | HCC2 | Human | Liver | HCC | 6.60e-36 | 1.81e+00 | 0.5341 |
| 6538 | SLC6A11 | HCC5 | Human | Liver | HCC | 3.93e-42 | 1.77e+00 | 0.4932 |
| 6538 | SLC6A11 | S016 | Human | Liver | HCC | 1.08e-02 | 5.23e-02 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC6A11 | SNV | Missense_Mutation | rs756798347 | c.1048N>G | p.Phe350Val | p.F350V | P48066 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| SLC6A11 | SNV | Missense_Mutation | rs756798347 | c.1048N>G | p.Phe350Val | p.F350V | P48066 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLC6A11 | SNV | Missense_Mutation | novel | c.1235N>C | p.Phe412Ser | p.F412S | P48066 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| SLC6A11 | SNV | Missense_Mutation | rs756798347 | c.1048N>G | p.Phe350Val | p.F350V | P48066 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SLC6A11 | SNV | Missense_Mutation | rs774891377 | c.1142C>T | p.Ala381Val | p.A381V | P48066 | protein_coding | tolerated(0.14) | possibly_damaging(0.881) | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| SLC6A11 | SNV | Missense_Mutation | c.881N>G | p.Ser294Cys | p.S294C | P48066 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
| SLC6A11 | SNV | Missense_Mutation | c.107C>T | p.Ala36Val | p.A36V | P48066 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC6A11 | SNV | Missense_Mutation | rs753638124 | c.664N>A | p.Gly222Arg | p.G222R | P48066 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC6A11 | SNV | Missense_Mutation | c.608T>A | p.Val203Asp | p.V203D | P48066 | protein_coding | deleterious(0.01) | possibly_damaging(0.853) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| SLC6A11 | SNV | Missense_Mutation | rs548624556 | c.1357N>A | p.Val453Met | p.V453M | P48066 | protein_coding | tolerated(0.11) | possibly_damaging(0.689) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6538 | SLC6A11 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GSK683699 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |